19. Guo X, Zhang X, Zheng L. Prehypertension is not associated with all-cause mortality: a systematic review and meta-analysis of prospective studies. PLoSONE 2013; 8: e61796
20. Gonzalez. A. Morbi mortalidad por enfermedad cerebro vascular de tipo isquémica. Rev Cubana Med Gen Integr 2007;23(4) Disponible en : http://scielo.sld.cu/scielo.php?script=sci_abstract&pid=S1729-519X2009000100006&lng=es&nrm=iso&tlng=es
21. Sox HC. Assessing the trustworthiness of the guide line for management of high blood pressure in adults. JAMA 2014; DOI:10.1001/jama.2013.284429. Available at: http://jama.jamanetwork.com/journal.aspx.
22. Alberti KG, Eckel RH, Grundy SM. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Iinstitute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120: 1640–5 .
23. Eckel RH, Alberti KGMM, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2010; 375: 181–3
24. Glasser SP, Judd S, Basile J, Lackland D. Prehypertension, racial prevalence and association with risk factors: analysis of the reasons for geographic and racial differences in stroke (REGARDS) study. Am. J. Hypertens 2011; 24: 194–9
25. Weiss R, Bremer AA, Lustig RH. What is metabolic syndrome, and why are children getting it? Ann. N Y Acad. Sci.2013; 1281: 123–40 .
26. Drager LF, Togeiro SM, Polotsky VY, Lorenzi-Filho G. Obstructive sleep apnea: a cardiometabolic risk in obesity and metabolic syndrome. J. Am. Coll. Cardiol 2013; 62: 569–76
27. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991;265:3255–3264.
28. Mancia G, Fagard R, Narkiewicz K , Redon J, Zanchetti A. 2013 ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34,.2159-79
29. Dahlof B, Sever PS, Poulter NR, for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895-906
30. Williams B, Lacy PS, Thom SM. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study Circulation 2006;113:1213-25.
31. Arredondo Bruce. Alfredo: Beta-bloqueadores en la hipertensión arterial: ¿podemos descartarlos? [Internet] AMC Camagüey mar.-abr.[Último acceso julio 2014] 2010;14 (2)Disponible en: http://scielo.sld.cu/cgi-bin/wxis.exe/iah/
32. Ameriso, S F. Ruiz Villamil, A.Pérez Barreto, M. Infección, inflamación e ictus cerebral. Rev Esp Cardiol Supl. 2004;4(G):7-12
33. Shaw JG, Dent AG, Passmore LH. Genetic influences on right ventricular systolic pressure (RVSP) in chronic obstructive pulmonary disease (COPD). BMC Pulm. Med.2012; 12- 25
34. Ellsworth DL, Croft D, Weyandt J. Intensive cardiovascular risk reduction induces sustainable changes in expression of genes and pathways important to vascular function. CircCardiovasc Genet 2014; 10: 1161-21.
35. Mega JL, Simon T, Collet JP. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304:1821-30